Celltrion's biosimilar Remsima reborn as subcutaneous injection

Lim Chang-won Reporter Posted : 2018-12-03 10:14 Updated : 2018-12-03 10:14
글씨작게 글씨크게


SEOUL -- South Korea's leading biosimilar manufacturer, Celltrion, has developed a subcutaneous injection of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease, to enhance patient convenience and access to medical care.

Celltrion said Monday that Remsima SC has applied for approval by the European Medicines Agency. Instead of an intravenous injection that takes more than two hours in hospital, patients can inject Remsima SC into the fat layer beneath the skin along at home. Currently, Remicade (Infliximab) biosimilar exist in the form of conventional intravenous injection.

Celltrion has produced biosimilars such as Herzuma, used to treat breast cancer based on Herceptin developed by Genentech, a subsidiary of Swiss pharmaceutical giant Roche. Last week, Truxima, the first biosimilar to Rituxan (rituximab), was approved by the Food and Drug Administration.